At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIAF bioAffinity Technologies, Inc.
Trading 08-10 11:15:47 EDT
0.5190
+0.0090
+1.76%
High0.5200Low0.5000Vol220.14K
Open0.5000D1 Closing0.5100Amplitude3.92%
Mkt Cap4.20MTradable Cap4.16MTotal Shares8.10M
T/O112.89KT/O Rate2.74%Tradable Shares8.02M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Heron Therapeutics Q2 Revenue Rises on Acute Care Growth, Withdraws 2026 Outlook
Reuters  ·  20:08
Heron Therapeutics Q2 Revenue Rises on Acute Care Growth, Withdraws 2026 Outlook
bioAffinity Technologies Q2 Net Income USD -3.4 Million
THOMSON REUTERS  ·  08-07
bioAffinity Technologies Q2 Net Income USD -3.4 Million
bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate
Benzinga Earnings  ·  08-07
bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate
bioAffinity Q2 FY26 Net Loss Narrows to $3.4 Million; Revenue Rises 19% to $1.5 Million
Reuters  ·  08-07
bioAffinity Q2 FY26 Net Loss Narrows to $3.4 Million; Revenue Rises 19% to $1.5 Million
Press Release: bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung
Dow Jones  ·  08-07
Press Release: bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung
bioAffinity Technologies Faces NASDAQ Delisting Risk After Shares Trade Below $1 Bid-price Minimum
Reuters  ·  08-01
bioAffinity Technologies Faces NASDAQ Delisting Risk After Shares Trade Below $1 Bid-price Minimum
BioAffinity announces publication of clinical review on CyPath Lung
TIPRANKS  ·  07-27
BioAffinity announces publication of clinical review on CyPath Lung
bioAffinity Publishes Clinical Framework Targeting Pulmonary Nodule Risk Stratification Market
Reuters  ·  07-27
bioAffinity Publishes Clinical Framework Targeting Pulmonary Nodule Risk Stratification Market
Bioaffinity Technologies - Tests Expected to be Offered as Laboratory Developed Tests Under Clia
THOMSON REUTERS  ·  07-22
Bioaffinity Technologies - Tests Expected to be Offered as Laboratory Developed Tests Under Clia
Bioaffinity Technologies - Partners with Pictor to Develop Asthma and Copd Diagnostics
THOMSON REUTERS  ·  07-22
Bioaffinity Technologies - Partners with Pictor to Develop Asthma and Copd Diagnostics
Bioaffinity Quarterly Cypath Lung Test Sales Double, up More than 200% Year over Year
Reuters  ·  07-07
Bioaffinity Quarterly Cypath Lung Test Sales Double, up More than 200% Year over Year
Bioaffinity to Join Navref-hosted Webinar on Philips-led US Veterans Lung Screening Program
Reuters  ·  07-01
Bioaffinity to Join Navref-hosted Webinar on Philips-led US Veterans Lung Screening Program
BioAffinity will present preclinical findings on small interfering RNAs
TIPRANKS  ·  06-22
BioAffinity will present preclinical findings on small interfering RNAs
bioAffinity reports positive preclinical data for siRNA therapy targeting squamous, basal skin cancer cells
Reuters  ·  06-22
bioAffinity reports positive preclinical data for siRNA therapy targeting squamous, basal skin cancer cells
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
THOMSON REUTERS  ·  06-22
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
BioAffinity Technologies Closes $3.2 Million Public Offering
MT Newswires Live  ·  06-19
BioAffinity Technologies Closes $3.2 Million Public Offering
bioAffinity Technologies closes USD 3.2 million follow-on offering priced at USD 0.8 per share
Reuters  ·  06-19
bioAffinity Technologies closes USD 3.2 million follow-on offering priced at USD 0.8 per share
bioAffinity Technologies Announces Closing of $3.2 Million Offering
THOMSON REUTERS  ·  06-19
bioAffinity Technologies Announces Closing of $3.2 Million Offering
bioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13%
MT Newswires Live  ·  06-17
bioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13%
BioAffinity Technologies prices 4M shares at 80c in public offering
TIPRANKS  ·  06-17
BioAffinity Technologies prices 4M shares at 80c in public offering

Introduction

Company Name.
bioAffinity Technologies, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Issue price:
--